PCSK9 Inhibitors in Primary Cardiovascular Prevention: A Multi-Cohort Comparative Effectiveness Study of Evolocumab and Alirocumab versus Oral Dual Lipid-Lowering Therapy Using Real-World Electronic Health Records (AHA 2026) - Sep 5, 2026 - Abstract #Su3070; Pres time: Nov 8, 2026; 03:15 PM - 04:15 PM; Location: Population Science Zone‚ Science and Technology Hall‚ South Hall‚ Leve; In-Person; Board no. 3070; No abstract available
Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular
|
|
Qusai Alqudah; Hamzeh Alshahwan; Tala Altarawneh; Ahmad Assad; Adee Elhamdani; Abdallah Rayyan; Ola Shaltout
|